Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study
HematologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Haematologica
- Publicado em
- 30 jan 2025
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study
Muhit Özcan, Ryan D Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Ying Chen, Alejandra Nieto, Fatih Demirkan, Pau Montesinos, Fevzi Altuntas
Descritores MeSH
- Inotuzumab Ozogamicin
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Antineoplastic Agents, Immunological
- Aged
- Female
- Hepatic Veno-Occlusive Disease
- Humans
- Male
- Middle Aged
- Treatment Outcome
Veja também
Estudos relacionados
- Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review
- Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL
- Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis